<DOC>
	<DOCNO>NCT01908829</DOCNO>
	<brief_summary>The purpose study see add new type medication recently approve treat overactive bladder ( mirabegron ) antimuscarinic treatment ( solifenacin ) effective control incontinence use antimuscarinic treatment alone .</brief_summary>
	<brief_title>A Trial Comparing Combination Treatment ( Solifenacin Plus Mirabegron ) With One Treatment Alone ( Solifenacin )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Main Inclusion Screening : 1 . Subject symptom OAB ( urinary frequency urgency urgency incontinence ) &gt; = 3 month prior screen visit 2 . Subject willing able complete micturition diary questionnaire correctly , include collection measurement urine output 3 day prior visit ; 3 . Subject symptom `` wet '' OAB ( urinary frequency urgency incontinence mixed incontinence predominant urgency incontinence ) , report average least 2 incontinence episode per day . Main Inclusion Runin ( Visit 2 ) : 1 . Subject experience average least 1 episode urgency ( grade 3 4 ) without incontinence per 24hour period 3day micturition diary period . 2 . Subject experience average least 2 incontinence episode per 24hour period 3day micturition diary period . 3 . Subject experience average least 8 micturition ( exclude incontinence episode ) per 24hour period 3day micturition diary period . Main Inclusion Randomization ( Visit 3 ) : 1 . Subject experience least 1 incontinence episode 3day micturition diary period wish increase treatment OAB symptom . Main Exclusion Screening : 1 . Subject opinion investigator clinically significant Bladder Outlet Obstruction ( BOO ) . 2 . Subject significant Postvoid residual ( PVR ) volume ( PVR &gt; 150 ml ) . 3 . Subject significant stress incontinence mixed stress/urgency incontinence stress predominant factor determine investigator 4 . Subject indwell catheter practice intermittent self catheterization . 5 . Subject evidence UTI . 6 . Subject chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy , previous current malignant disease pelvic organs 7 . Subject moderate severe hepatic impairment 8 . Subject severe renal impairment End Stage Renal disease 9 . Subject clinically significant abnormal Electrocardiogram ( ECG ) 10 . Subject concurrent malignancy history cancer ( except noninvasive skin cancer ) within last 5 year prior screen . 11 . Subject QTcF interval &gt; 450 m male &gt; 470 m female risk QT prolongation ( e.g. , family history long QT syndrome , hypokalaemia ) . 12 . Subject receive intravesical treatment past 12 month e.g. , botulinum toxin , resiniferatoxin , capsaicin . 13 . Subject severe uncontrolled hypertension , define sit average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg . Main Exclusion Randomization ( visit 3 ) : 1 . Subject achieve 100 % continence Visit 2 Visit 3 ( incontinence episode record 3 day diary administer 3 day prior Visit 3 ) . 2 . Subject desire increase study medication . 3 . Subject average total daily urine volume &gt; 3000ml record micturition diary . 4 . Subject severe uncontrolled hypertension , define sit average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg . 5 . Subject clinically significant abnormal ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Overactive Bladder ( OAB )</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urgency incontinence</keyword>
	<keyword>Frequency</keyword>
	<keyword>Urgency</keyword>
	<keyword>Micturition</keyword>
	<keyword>YM178</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Betmiga</keyword>
	<keyword>Myrbetriq</keyword>
	<keyword>Betanis</keyword>
	<keyword>Vesicare</keyword>
	<keyword>Vesitrim</keyword>
	<keyword>Vesikur</keyword>
	<keyword>YM905</keyword>
</DOC>